Skip to content

'Shugan Hewei' decoction combined with Rabeprazole with the treatment of refractory gastroesophageal reflux disease: a multicenter, parallel, double-blind randomized controlled trial

'Shugan Hewei' decoction combined with Rabeprazole with the treatment of refractory gastroesophageal reflux disease: a multicenter, parallel, double-blind randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009652
Enrollment
Unknown
Registered
2016-10-27
Start date
2016-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory gastroesophageal reflux disease

Interventions

Group of TCM syndrome differentiation + PPI :TCM syndrome differentiation + PPI
Group of Agreement prescription of traditional Chinese Medicine+PPI: Agreement prescription of traditional Chinese Medicine+PPI

Sponsors

Shanghai Yueyang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) In accordance with gastroesophageal reflux disease western medicine and traditional Chinese medicine diagnostic criteria; (2) The failed treated gastroesophageal reflux disease by taken the first generation of PPI continuely for four weeks or longer in the present study; (3) Aged 18-70 years male or female.

Exclusion criteria

Exclusion criteria: 1) With one of the following diseases: peptic ulcer, esophageal and gastric and duodenal surgery, Zollinger Ellison syndrome, primary esophageal motility disorders (such as achalasia, scleroderma, primary esophageal spasm), upper gastrointestinal malignant lesions, drug esophagitis, and psychiatric patients. 2) Pregnant women and lactating women; 3) The liver and kidney function is obviously abnormal (AST, ALT, the creatinine value is higher than the normal value range one and a half); 4) The person who can not cooperate with the treatment, can not take medicine on time and carry on the related examnation; 5) The patients themselves are directly involved in the research of the clinical research.

Design outcomes

Primary

MeasureTime frame
Safety index;Effect index;

Secondary

MeasureTime frame
Evaluation index;

Countries

China

Contacts

Public ContactWANG XIAOSU

Shanghai Yueyang Hospital

xswangxs0084@163.com+86 18930565281

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026